Affinity DataIC50: 3nMAssay Description:p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 3nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 5nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Method 2: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to t...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Method 1The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 6nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Method 2: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to t...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:p38 MAPKα Method 2: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 8nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Homo sapiens (Human))
Topivert Pharma Limited
US Patent
Topivert Pharma Limited
US Patent
Affinity DataIC50: 8nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Method 1: The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determinin...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Method 1The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:Method 1The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen) are evaluated indirectly by determining the level...More data for this Ligand-Target Pair
Affinity DataIC50: 8nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
